AstriVax aims for initial clinical validation of the platform technology, to develop a broad vaccination pipeline. Based on vaccination technologies created at the Rega Institute and launched in 2022, AstriVax is a privately held spin-off firm from KU Leuven. AstriVax is developing a first-of-its-kind Plug & Play vaccination platform using patented DNA-based technology that releases live attenuated viruses that self-amplify. An extensive range of vaccines for the prevention and treatment of infectious illnesses can be created using the flexible technology of AstriVax.
Pipeline, Vaccination, DNA-based technology
Between €2.5 million-5 million
💡 You're a corporate or investor and looking for startups that are innovating in the same market as AstriVax? We're happy to assist you with our Startup Sourcing service.